Molecular and clinical profiling

分子和临床分析

• 批准号: 8349494
• 负责人: Carl Ola Landgren
• 金额: $ 112.56万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8349494
• 关键词: Back; Clinical; Clinical Management; Data; Development; Disease; Early treatment; Future; Generations; Goals; Modality; Molecular; Molecular Profiling; Monoclonal Antibodies; Monoclonal gammopathy of uncertain significance; Multiple Myeloma; Natural Killer Cells; Outcome; Patients; Plasma Cells; Staging; base; bone; design; high risk; molecular imaging; novel; prevent

If we will provide a better understadning of underlying mechanisms of myelomagenesis, then we will be able to reach are goals to (1) define high-risk precursor disease patinets, and to (2) delay and prevent development of multiple myeloma. For example, in 2010, we opened a treatment study for smoldering, using a novel treatment approach modality (a monoclonal antibody which targets natural killer cells, which in turn will cause anti-myeloma effect). We are now developing the second generation of treatment studies based on our generated data from the molecular profiling studies we are doing in parallel. If we will be able to goals to delay/prevent myeloma, it will have a major impact on the clinical management and outcome for these patients in the future.

如果我们将更好地了解骨髓造成的潜在机制，那么我们将能够实现的目标是（1）定义高风险的前体病patinets，以及（2）延迟和防止多发性骨髓瘤的发展。例如，在2010年，我们使用一种新的治疗方法模态（一种针对天然杀伤细胞的单克隆抗体，这将引起抗肌瘤作用）。现在，我们正在根据我们正在同行进行的分子分析研究中生成的数据开发第二代治疗研究。如果我们能够延迟/预防骨髓瘤，那么将来将对这些患者的临床管理和结果产生重大影响。